Webber & Grinnell Supports CDH Cancer Center Campaign
NORTHAMPTON — Webber & Grinnell Insurance can trace its local origins all the way back to 1849, when the town....
Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir. Gilead's bictegravir, another so-called integrase inhibitor drug, delivered 97 percent virus suppression, making it just as effective as GSK's product, data presented at a medical meeting in Seattle late on Monday showed. Importantly, there were no cases of resistance emerging to the new medicine in the 98-patient Phase II study and no patients discontinued treatment due to kidney problems, which can be an issue with HIV treatments.
Having all those calories and sugar delivered quickly to your body by a liquid isn’t healthy, experts say.